TrialPhase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
Trial details
- Registry ID
- NCT05232916
- Phase
- Phase 3
GLSI
Greenwich LifeSciences, Inc.
Company identity checked against sources
Browse linked trials and recorded changes, or follow this company for updates.
1Trials in this database
2Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
Completion dates · Pro
Which trial dates moved later?
Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features
Included trials
Check company identity source| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive SubjectsNCT05232916 | GLSI | Phase 3 | Recruiting | 2031-12Estimated |
Latest recorded trial changes
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
NCT05232916 · Greenwich LifeSciences, Inc.
Planned enrollment increased by 1500 participants
− Before
750 participants (planned)
+ After
2250 participants (planned)
Primary completion date changed
− Before
Dec 2026
+ After
Dec 2031